Non-Hodgkin's lymphoma

Current Opinion in Hematology

Volumn 3, Issue 4, 1996, Pages 266-272

  Bierman, Philip J ^a   Armitage, James O ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MARROW TRANSPLANTATION; CANCER GRADING; CANCER SURVIVAL; DOSE CALCULATION; HELICOBACTER PYLORI; HIGH RISK POPULATION; HUMAN; LYMPHOID TISSUE; MULTIMODALITY CANCER THERAPY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT PLANNING;

EID: 0030036920     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199603040-00004     Document Type: Review

References (78)

1. Parker SL, Tong T, Bolden S, Wingo P: Cancer statistics, 1996. CA Cancer J Clin 1996, 65:5-27.
2. Greiner TC, Medeiros LJ, Jaffe ES: Non-Hodgkin's lymphoma. Cancer 1995, 75:370-360.
3. Aisenberg AC: Coherent view of non-Hodgkin's lymphoma. J Clin Oncol 1995, 13:2656-2675. This is a thorough, extensively referenced review of the epidemiology, pathogenssis, classification, and treatment of non-Hodgkin's lymphoma.
4. Harris NL, Jaffe ES, Stein H, Bank PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, et al.: A revised European-American classification of tymphold neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84:1361-1392. This article presents a proposal by 19 expert hematopathologists for a new classification system for lymphomas. The histologic, immunologic, and genetic features, as well as the clinical features of the entities in the proposed classification system are thoroughly reviewed.
5. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's Lymphoma. N Engl J Med 1993, 329:987-994.
6. Gordon LI, Andersen J, Colgan J, Glick J, Resnick GD, O'Connell M, Cassileth PA: Advanced diffuse non-Hodgkin's lymphoma. Cancer 1995, 75:865-873.
7. Hermans J, Krol ADG, van Groningen K, Kluin PhM, Kluin-Nelemans JC, Kramer MHH, Noordijk EM, Ong F, Wijermans PW: International prognostic index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 1995, 86:1460-1463.
8. Martin AR, Weisenburger DD, Chan WC, Ruby EI, Anderson JR, Vose JM, • Bierman PJ, Bast MA, Daley DT, Armitage JO: Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood 1995, 85:3671-3678. This article compares four different classification methods for follicular lymphoma and concludes that the Berard method is most useful for predicting survival.
9. Suki S, Swan F Jr, Tucker S, Fritsche HA, Redman JR, Rodriguez MA, Mclaughlin P, Romaguera J, Hagemeister FB, Velasquez WS, Sarris AH, Younes A, Cabanillas F: Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase. Leuk Lymphoma 1995, 18:87-92.
10. Yan Y, Chan WC, Weisenburger DD, Anderson JR, Bast MA, Vose JM, Bierman PJ, Armitage JO: Clinical and prognostic significance of bone marrow involvement in patients with diffuse aggressive B-cell lymphoma. J Clin Oncol 1995, 13:1336-1342.
11. Piris MA, Villuendes R, Martinez JC, Sanchez-Beato M, Orradre JL, Mateo • MS, Martinez P: p53 Expression in non-Hodgkin's lymphomas: a marker of p53 inactivation? Leuk Lymphoma 1995, 17:35-42. A good review of the p53 gene and its function. The role of p53 mutations in non-Hodgkin's lymphoma is discussed.
12. Preudhomme C, Dervite I, Wattel E, Vanrumbeke M, Flactif M, Luc Lai J, Hecquet B, Coppin MC, Nelken B, Gosselin B, Fenaux P: Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: a report of 48 cases. J Clin Oncol 1995, 13:812-820.
13. Louie DC, Offit K, Jaslow R, Parsa NZ, Murty VVVS, Schluger A, Chagnati RSK: p53 Overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14) (q13;q32). Blood 1995, 86:2892-2899.
14. Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R: Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 1995, 13:575-582.
15. Stauder R, Eisterer W, Thaler J, Günthert U: CD44 Variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood 1995, 85:2885-2899.
16. Hermine O, Haioun C, Lepage E, d'Agay M-F, Briere J, Lavignac C, Fillet G, Salles G, Marolleau J-P, Diebold J, Reyes F, Gaulard P: Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 1996, 87:265-272. The expression of bcl-2 protein was examined in 290 patients with non-Hodgkin's lymphoma. High expression was identified in 45% of cases and was associated with advanced stage and poor survival in the subset of patients with B-cell diffuse large-cell lymphoma.
17. Witzig TE, Habermann TM, Kurtin PJ, Schroeder G, Stenson MJ, Greipp PR: S-phase fraction by the labeling index as a predictive factor for progression and survival in low grade non-Hodgkin's lymphoma. Cancer 1995, 76:1059-1064.
18. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick •• JH, Coltman CA Jr, Miller TP: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993, 328:1002-1006. This phase III trial conducted by the Southwest Oncology Group and the Eastern Cooperative Oncology Group randomly assigned 899 patients with aggressive lymphoma to receive CHOP, MACOP-B, M-BACOD, or ProMACE-CytaBOM. No significant differences in response rate, time to treatment failure, or overall survival were observed. The authors concluded that CHOP is the optimal treatment for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
19. Silingardi V, Federico M, Cavanna L, Avanzini P, Gobbi PG, Lombardo M, Carotenuto M, Frassoldati A, Pieresca C, Vallisa D, Merli F, Ascari E, Mauri C: ProMACE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long-term results of a multicenter study of the Italian Lymphoma Study Group (GISL). Leuk Lymphoma 1995, 17:313-320.
20. Mazza P, Zinzani PL, Martelli M, Fiacchini M, Bocchia M, Pileri S, Falini B, Martelli MF, Amadori S, Papa G, et al.: MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas. Leuk Lymphoma 1995, 16:457-463.
21. De Lena M, Ditonno P, Lorusso V, Brandi M, Timurian A, Marzullo F, Ventrella V, Pellecchia A: CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study. J Clin Oncol 1995, 13:953-960.
22. Fridrik MA, Hausmaninger H, Linkesch W, Stöger M, Sill H, Neubauer M, Seewann HL, Klocker J, Haidinger R, Schiller L, Pont J, Raudaschl G, Falk M, Radaszkiewicz T: CEOP-IMVP-DEXA in the treatment of aggressive lymphomas: an Austrian multicenter trial. J Clin Oncol 1996, 14:227-232.
23. Bezwoda W, Rastogi RB, Erazo Valla A, Diaz-Maqueo JC, Pavlovsky S, Morioka H, Resegotti L, Rueckle H, Somoza N, Moreno-Nogueira JA, Bernasconi C, Ho A, Burns I, Lardinois J, van der Merwe A, Richards E: Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate- and high-grade non-Hodgkin's lymphomas. Eur J Cancer 1995, 31A:903-911.
24. Sonneveld P, de Ridder M, van der Lelie H, Nieuwenhuis K, Schouten H, Mulder A, van Reijswoud I, Hop W, Löwenberg B: Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995, 13:2530-2539.
25. Meyer RM, Quirt IC, Skillings JR, Cripps MC, Bramwell VHC, Weinerman BH, Gospodarowicz MK, Bums BF, Sargeant AM, Shepherd LE, Zee B, Hryniuk WM: Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. N Engl J Med 1993, 329:1770-1776.
26. Parker BA, Petroni GR, Canellos GP, Gockerman JP, Cooper MR, Omura GA, Johnson JL, Peterson BA: Dose-Intensified cyclophosphamide (C) and etoposida (E) in CHOP plus E (CHOPE) therapy of diffuse lymphomas (IWF E-H). CALGB 8852 [abstract 1522]. Blood 1994, 84(suppl 1):384a.
27. 2.
28. Meyer RM, Browman GP, Samosh ML, Benger AM, Bryant-Lukosius D, Edwin W, Wilson C, Frank GL, Leber BF, Stembach MS, Foster GA, Skingley P, Levine MN: Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 1995, 13:2386-2393.
29. Nademanee A, Schmidt GM, O'Donnell MR, Snyder DS, Parker PA, Stein A, Smith E, Lipsett JA, Sniecinski I, Margolin K, Somlo G, Niland JC, Blume KG, Forman SJ: High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: a pilot study. Blood 1992, 80:1130-1134.
30. Freedman AS, Takvonan T, Neuberg D, Mauch P, Rabinowe SN, Anderson KC, Soiffer RJ, Spector N, Grossbard M, Robertson MJ, Blake K, Coral F, Canellos GP, Ritz J, Nadler LM: Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study. J Clin Oncol 1993, 11:931-936.
31. Jost LM, Jacky E, Dommann-Scherrer C, Honegger H-P, Maurer R, Sauter C, Stahel RA: Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients. Ann Oncol 1995, 6:445-451.
32. Haioun C, Lepage E, Gisselbrecht C, Coiffier B, Bosly A, Tilly H, Morel P, Nouvel C, Herbrecht R, D'Agay MF, Gaulard P, Reyes F: Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. J Clin Oncol 1994, 12:2543-2551. This large French trial randomly assigned 464 patients with non-Hodgkin's lymphoma in first complete remission to receive conventional chemotherapy consolidation or high-dose chemotherapy consolidation with autologous bone marrow transplantation. No significant difference in outcome was observed, although a trend in favor of improved disease-free survival was seen for poor-prognosis patients. Follow-up data have now shown that poor-prognosis patients do have improved overall survival and many physicians are now recommending early transplantation for these patients.
33. Haioun C, Lepage E, Gisselbrecht Ch, Coiffier B, Bosly A, Dupriez B, Nouvel C, Tilly H, Lederlin P, Biron P, Brière J, Gaulard Ph, Reyes F: Autologous bone marrow transplantation (ABMT) versus sequential chemotherapy for aggressive non-Hodgkin's lymphoma (NHL) in first complete remission (CR): a study of 542 patients [abstract 1816]. Blood 1995, 86(suppl 1):457a.
34. Pettengell R Radford JA, Morgenstern GR, Scarffe JH, Harris M, Woll PJ, Deakin DP, Ryder D, Wilkinson PM, Crowther D: Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma. J Clin Oncol 1996, 14:586-592. This trial demonstrated that patients with poor-prognosis non-Hodgkin's lymphoma who undergo autologous peripheral stem cell transplantation in first remission had significantly better event-free and overall survival than similar patients treated with standard therapy.
35. Goss P, Shepherd F, Scott JG, Baker M, Sutton D, Sutcliffe S: DICE (dexamethasone, ifosfamide, cisplatin, etoposide) as salvage therapy in non-Hodgkin's lymphomas. Leuk Lymphoma 1995, 18:123-129.
36. Rodriguez MA, Cabanillas FC, Velasquez W, Hagemeister FB, McLaughlin P, Swan F, Romaguera JE: Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 1995, 13:1734-1741.
37. Wilson WH, Bates SE, Fojo A, Bryant G, Zhan Z, Regis J, Wittes RE, Jaffe ES, Steinberg SM, Herdt J, Chabner BA: Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 1995, 13:1995-2004.
38. Wilson WH, Chabner BA, Bryant G, Bates S, Fojo A, Regis J, Jaffe ES, Steinberg SM, Goldspiel BR, Cheson BD, Wittes RE: Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. J Clin Oncol 1995, 13:381-386.
39. Younes A, Sams A, Melnyk A, Romaguera J, McLaughlin P, Swan F, Rodriguez MA, Hagemeister F, Moore D, North L, Smith TL, Cabanillas F: Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. J Clin Oncol 1995, 13:583-587.
40. DeNardo GL, Lambom KR, DeNardo SJ, Godstein DS, Dolber-Smith EG, Kroger LA, Larkin EC, Shen S: Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies. Cancer Res 1995, 55(suppl 1):5893s-5898s.
41. Juweid M, Sharkey RM, Markowitz A, Behr T, Swayne LC, Dünn R, Hansen HJ, Shevitz J, Leung S-O, Rubin AD, Herskovic T, Hanley D, Goldenberg DM: Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res 1995, 55(suppl 1):5899s-5907s.
42. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995, 346:336-340. Patients with relapsed non-Hodgkin's lymphoma had a 2-year overall survival of 93% and a progression-free survival of 62% following treatment with a radiolabeled antibody directed against CD20.
43. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D, •• Sonneveld P, Gisselbrecht C, Cahn J-Y, Harousseau J-L, Coiffier B, Biron P, Mandelli F, Chauvin F: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995, 333:1540-1545. This large trial has provided convincing evidence for the superiority of high-dose therapy over conventional salvage chemotherapy for patients with relapsed non-Hodgkin's lymphoma. Patients in sensitive relapse were randomly assigned to receive additional conventional salvage chemotherapy or to receive high-dose chemotherapy followed by autologous bone marrow transplantation. Overall survival and event-free survival were significantly better in patients receiving transplants.
44. Bennett CL, Armitage JL, Armitage GO, Vose JM, Bierman PJ, Armitage JO, Anderson JR: Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991. J Clin Oncol 1995, 13:969-973.
45. Shipp MA: Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease? Blood 1994, 83:1165-1173. An excellent review of prognostic factors for lymphoma divided into those relating to the host or tumor, those relating to clinical characteristics, and those related to treatment. Cellular and molecular features associated with prognosis are discussed.
46. Verdonck LF, van Putten WLJ, Hagenbeek A, Schouten HC, Sonneveld P, van Imhoff GW, Kluin-Nelemans HC, Raemaekers JMM, van Oers RHJ, Haak HL, Schots R, Dekker AW, de Gast GC, Löwenberg B: Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995, 332:1045-1051.
47. Martelli M, Vignetti M, Zinzani PL, Gherlinzoni F, Meloni G, Fiacchini M, De Sanctis V, Papa G, Martelli MF, Calabresi F, Tura S, Mandelli F: High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study. J Clin Oncol 1996, 14:534-542.
48. Johnson PWM, Rohatiner AZS, Whelan JS, Price CGA, Love S, Lim J, Matthews J, Norton AJ, Amess JAL, Lister TA: Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995, 13:140-147.
49. Tallman MS, Hakimian D: Purine nucleoside analogs: emerging roles in Indolent lymphoproliferative disorders. Blood 1995, 86:2463-2474. An excellent review of the pharmacology and treatment results of the purine analogues.
50. Saven A, Emanuele S, Kosty M, Koziol J, Ellison D, Piro L: 2-Chlorodeoxydenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood 1995, 86:1710-1716.
51. Solal-Cèeligny P, Brice P, Brousse N, Caspard H, Bastion Y, Haïioun C, Bosly A, Tilly H, Bordessoule D, Sebban C, Harousseau JL, Morel P, Dupas B, Plassart F, Vasile N, Fort N, Leporrier M: Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1996, 14:514-519.
52. Rohatiner AZS, Johnson PWM, Price CGA, Amott SJ, Amess JAL, Norton AJ, Dorey E, Adams K, Whelan JS, Matthews J, MacCallum PK, Oza AM, Lister TA: Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994, 12:1177-1184.
53. Cervantes F, Shu XO, McGlave PB, Ramsay NKC, Miller WJ, Kersey JH, Weisdorf DJ: Autologous bone marrow transplantation for non-transformed low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant 1995, 16:387-392.
54. Bastion Y, Brice P, Haioun C, Sonet A, Salles G, Marolleau JP, Espinouse D, Reyes F, Gisselbrecht C, Coiffier B: Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995, 86:3257-3262.
55. Haas R, Moos M, Möhle R, Döhner H, Witt B, Goldschmidt H, Murea S, Flentje M, Wannenmacher M, Hunstein W: High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant 1996, 17:149-155.
56. van Besien KW, Khouri IF, Giralt SA, McCarthy P, Mehra R, Andersson BS, Przepiorka D, Gajewski JL, Bellare N, Nath R, Romaguera JE, McLaugnlin P, Korbling M, Deisseroth AB, Cabanillas FF, Champlin RE: Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J Clin Oncol 1995, 13:1096-1102.
57. van Besien K, Rowlings PA, Sobocinski KA, Phillips G, Vose J, McCarthy P, Klein JP, Champlin R, Horowitz MM: Allogeneic bone marrow transplantation for low grade lymphoma [abstract 824], Blood 1995, 86(suppl 1):209a.
58. Wotherspoon AC, Finn TM, Isaacson PG: Trisomy 3 in low-grade B-call lymphomas of mucosa-associated lympoid tissue. Blood 1995, 85:2000-2004.
59. Isaacson PG: The MALT lymphoma concept updated. Ann Oncol 1995, 6:319-320.
60. Montalbáan C, Castrillo JM, Abraira V, Serrano M, Bellas C, Piris MA, Carrion R, Cruz MA, Larañna JG, Menarguez J, Gomez-Marcos F, Rivas C: Gastric B-cell mucosa-associated lymphoid tissue (MALT) lymphoma. Clinicopathological study and evaluation of the prognostic factors in 143 patients. Ann Oncol 1995, 6:355-362.
61. Roggero E, Zucca E, Graziella P, Pascarella A, Capella C, Savio A, • Pedrinis E, Paterlini A, Venco A, Cavalli F: Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 1995, 122:767-769. Treatment directed against H. pylori resulted in regression of gastric MALT lymphomas in 15 of 25 evaluable patients.
62. Beyerdörffer E, Neubauer A, Rudolph B, Thiede C, Lehn N, Eidt S, Stolte • M: Regression of primary gastric lymphoma of mucosa-associated lympoid tissue type after cure of Helicobacter pylori infection. Lancet 1995, 345:1591-1594. Treatment directed against H. pylori resulted in complete or partial regression of gastric MALT lymphomas in 27 of 33 patients.
63. Savio A, Franzin G, Wotherspoon AC, Zamboni G, Negrini R, Buffoli F, Diss TC, Pan L, Isaacson PG: Diagnosis and posttreatment follow-up of Helicobacter pylori-positive gastric lymphoma of mucosa-associated lympoid tissue: histology, polymerase chain reaction, or both? Blood 1996, 87:1255-1260.
64. Marchetti M, Aricóo B, Burroni D, Figura N, Rappuoli R, Ghiara P: Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science 1995, 267:1655-1658.
65. Zucca E, Stein H, Coiffier B: European Lymphoma Task Force (ELTF): report of the workshop on mantle cell lymphoma (MCL). Ann Oncol 1994, 5:507-511.
66. Hosokawa Y, Arnold A: Cyclin D1/PRAD1 as a central target in oncogenesis. J Lab Clin Med 1996, 127:246-252. A review of PRAD1/cyclin-D1 function and role in mantle cell lymphoma and other conditions.
67. Montserrat E, Bosch F, Lòpez-Guillermo A, Graus F, Terol M-J, Campo E, Rozman C: CNS involvement in mantle-cell lymphoma. J Clin Oncol 1996, 14:941-944.
68. Norton AJ, Matthews J, Pappa V, Shamash J, Love S, Rohatiner AZS, Lister TA: Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period. Ann Oncol 1995, 6:249-256.
69. Segal GH, Masih AS, Canavan Fox A, Jorgensen T, Sott M, Braylan RC: CD5-expressing B-cell non-Hodgkin's lymphoma with bcl-1 gene rearrangement have a relatively homogeneous immunophenotype and are associated with an overall poor prognosis. Blood 1995, 85:1570-1579.
70. Fisher RI, Dahlberg S, Nathwani BN, Banks PM, Miller TP, Grogan T: A •• clinical analysis of two indolent lymphoma entitles: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood 1995, 85:1075-1082. This Southest Oncology Group study evaluated the clinical response of patients with mantle cell lymphomas and marginal zone lymphomas in relation to other histologic subtypes. Patients with mantle cell lymphoma were found to have a significantly worse outcome than patients with other lymphomas.
71. Teodorovic I, Pittaluga S, Kluin-Nelemans JC, Meerwaldt JH, Hagenbeek A, van Glabbeke M, Somers R, Bijnens L, Noordijk EM, De Wolf Peeters C: Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. J Clin Oncol 1995, 13:2819-2826.
72. Zucca E, Roggero E, Pinotti G, Pedrinis E, Cappella C, Venco A, Cavalli F: Patterns of survival in mantle cell lymphoma. Ann Oncol 1995, 6:257-262.
73. Stewart DA, Vose JM, Weisenburger DD, Anderson JR, Ruby EI, Bast MA, Bierman PJ, Kessinger A, Armitage JO: The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann Oncol 1995, 6:263-266.
74. Werner MH, Phuphanich S, Lyman GH: The increasing incidence of malignant gliomas and primary central nervous system lymphoma in elderly. Cancer 1995, 76:1634-1642.
75. Blay J-Y, Conroy T, Chevreau C, Thyss A, Eghbali H, Bouabdallah R, Coiffier B, Wagner JP, Dramais-Marcel D, Baumelou E, Biron P: Analysis of 226 primary cerebral lymphomas treated in 10 centers in France between 1978 and 1993. A retrospective study from the Federation Nationale des Centres de Lutte Contre le Cancer [abstract 1086]. Blood 1995, 86(suppl 1):p275a.
76. Blay J-Y, Bouhour D, Carrie C, Bouffet E, Brunat-Mentigny M, Philip T, Biron P: The C5R Protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression. Blood 1995, 86:2922-2929.
77. Bessell EM, Graus F, Pung JAG, Firth JL, Hope DT, Moloney AJ, Lopez-Guillermo A, Villa S: Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy. J Clin Oncol 1996, 14:945-954.
78. Schultz C, Scott C, Sherman W, Donahue B, Fields J, Murray K, Fisher B, Abrams R, Meis-Kindblom J: Prelrradlatlon chemotherapy with cyclosphosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of Radiation Therapy Oncology Group protocol 88-06. J Clin Oncol 1996, 14:556-564.